YRRO Ltd agreed to acquire Hemcheck Sweden AB (publ) (OM:HEMC) in a reverse merger transaction for SEK 85.7 million on February 8, 2023. In exchange, Bio Vitos will receive 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck's share capital. It is anticipated that subject to all required shareholder and regulatory approvals, that Hemcheck will remain listed on the Nasdaq Stockholm.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1195 SEK | +10.65% | -25.78% | -49.79% |
02-14 | Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-14 | Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-49.79% | 2.97M | |
-4.67% | 12.33B | |
-5.19% | 8.14B | |
+28.50% | 5.62B | |
-8.09% | 4.24B | |
-55.31% | 3.06B | |
+13.49% | 2.76B | |
-1.34% | 2.41B | |
+32.24% | 2.23B | |
-3.55% | 1.87B |
- Stock Market
- Equities
- BIOVIT Stock
- News Bio Vitos Pharma AB
- YRRO Ltd agreed to acquire Hemcheck Sweden AB (OM: HEMC) in a reverse merger transaction for SEK 85.7 million.